All 255 curated trials

This trial is testing golidocitinib, a JAK1 inhibitor taken as a daily pill, against a placebo as maintenance therapy for patients with peripheral T-cell lymphoma who achieved a response after first-line chemotherapy and are not candidates for or have declined stem cell transplant. It is open to patients with PTCL-NOS, AITL, ALK-positive ALCL, or follicular T-cell lymphoma. Patients are randomly assigned to golidocitinib or placebo, and neither patients nor doctors know which they are receiving. This trial does not currently have sites in the United States.

This trial is studying whether high-dose chemotherapy followed by a stem cell transplant using the patient's own cells improves survival compared to observation alone in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. It is open to several PTCL subtypes including PTCL-NOS, angioimmunoblastic T-cell lymphoma (AITL), and ALK-negative anaplastic large cell lymphoma. This is a Phase 3 randomized trial, meaning patients are randomly assigned to either receive the transplant or continue with standard observation. This trial is widely available at 158 locations in the United States.

This trial is testing Soquelitinib for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. This trial is available at 21 locations in the United States. The trial is currently recruiting patients.

This trial is testing Low-dose total-skin electron-beam therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing XNW5004 tablets (an investigational oral drug) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing Belinostat and Pralatrexate either alone or in combination with CHOP chemotherapy for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment, as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 11 locations in the United States.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing TR115 (an EZH2 inhibitor) compared with investigator's choice of standard agents for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing golidocitinib (a daily oral JAK1 inhibitor) as maintenance therapy compared to placebo for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing CHOP (cyclophosphamide for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with cutaneous T-cell lymphoma (CTCL) or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Extracorporeal Photopheresis for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 3 locations in the United States. The trial is currently recruiting patients.

This trial is testing Durvalumab for patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 4 locations in the United States. The trial is currently recruiting patients.

This trial is testing AZD3470 for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

This trial is testing the combination of pembrolizumab (anti-PD-1) and mogamulizumab (anti-CCR4) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing DR-01 for patients with enteropathy-associated T-cell lymphoma, extranodal NK/T-cell lymphoma, hepatosplenic T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), or subcutaneous panniculitis-like T-cell lymphoma at various stages of their disease. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 15 locations in the United States. The trial is currently recruiting patients.

This trial is testing stem cell transplant for patients with adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), or T-cell prolymphocytic leukemia who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Mogamulizumab for patients with adult T-cell leukemia/lymphoma (ATLL) or cutaneous T-cell lymphoma (CTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.

This trial is testing Ruxolitinib for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Enasidenib for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

This trial is testing Brentuximab vedotin for patients with anaplastic large cell lymphoma (ALCL) or cutaneous T-cell lymphoma (CTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.

This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing tofacitinib 2% cream applied to the skin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing XNW5004 tablets (an investigational oral drug) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing PTX-100 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.

This trial is testing Ruxolitinib for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing BR101801 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing HH2853 Tablets for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing GFH009 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing brentuximab vedotin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

This trial is testing Golidocitinib for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Azacytidine for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.

This trial is testing Ifupinostat Hydrochloride for Injection for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing CD5-directed CAR-T cell therapy for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing a two-step haploidentical (half-matched) stem cell transplant using radiation-based reduced-intensity conditioning for patients with anaplastic large cell lymphoma (ALCL) or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing APG-115 for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Mogamulizumab for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Vinblastine (Velban) for patients with anaplastic large cell lymphoma (ALCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Drug:5-ALA for patients with adult T-cell leukemia/lymphoma (ATLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Riluzole for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.

This trial is testing a two-step haploidentical (half-matched) stem cell transplant using radiation-based reduced-intensity conditioning for patients with adult T-cell leukemia/lymphoma (ATLL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing STP938 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 3 locations in the United States. The trial is currently recruiting patients.

This trial is testing Genetic: MB-105 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 12 locations in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing XNW5004 tablets (an investigational oral drug) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Mogamulizumab for patients with adult T-cell leukemia/lymphoma (ATLL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 7 locations in the United States. The trial is currently recruiting patients.

This trial is testing ultra-low-dose total skin electron beam radiation therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Brentuximab vedotin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing LIS1 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Brentuximab Vedotin (Bv) for patients with anaplastic large cell lymphoma (ALCL) or cutaneous T-cell lymphoma (CTCL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Aclarubicin for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Adebrelimab & SHR2554 for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Benvitimod Cream for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Aclarubicin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing sintilimab (anti-PD-1) added to the P-GEMOX chemotherapy regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Mogamulizumab for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CD5-directed CAR-T cell therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (HDAC inhibitor) combined with azacitidine and other agents for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing JAK1 Inhibitor for patients with cutaneous T-cell lymphoma (CTCL) or extranodal NK/T-cell lymphoma who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CD7-directed CAR-T cell therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing sintilimab (anti-PD-1) added to the P-GEMOX chemotherapy regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing zeprumetostat (EZH2 inhibitor) in combination therapy for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing genotype-guided targeted agents added to CHOP chemotherapy (different agents matched to genetic subtypes) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CD30-directed CAR-T cell therapy (patient's own T cells engineered to attack CD30 on lymphoma cells) for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Mitoxantrone Hydrochloride Liposome & Enlonstobart for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing linperlisib (PI3Kδ inhibitor) combined with an EZH2 inhibitor for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Golidocitinib for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Lenalidomide for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Golicitinib combined with Pomadomide for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Golidocitinib plus CHOP for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Pembrolizumab IV infusion Q3W for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Linperlisib in combination with CHOP for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing selinexor combined with pegaspargase and dexamethasone for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2/3 trial that tests how well the treatment works and may compare it to standard care. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing a genotype-guided approach that adds different targeted drugs to standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. The specific targeted drug (such as azacitidine plus selinexor, decitabine plus selinexor, an EZH2 inhibitor plus chidamide, or azacitidine plus a JAK inhibitor) is chosen based on the genetic subtype of the lymphoma found by NGS testing. This is a Phase 1/2 randomized trial comparing the genotype-guided combination to CHOP alone. This trial does not currently have sites in the United States.

This trial is testing linperlisib combined with camrelizumab (anti-PD-1) and pegaspargase for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing EBV-specific T cells (immune cells trained to attack Epstein-Barr virus in lymphoma cells) for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing selinexor combined with pegaspargase and dexamethasone for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing XPO1 inhibitor for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (HDAC inhibitor) combined with azacitidine and other agents for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing zeprumetostat (EZH2 inhibitor) in combination therapy for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing EBV-specific T cells (immune cells trained to attack Epstein-Barr virus in lymphoma cells) for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Brigatinib for patients with ALK-positive anaplastic large cell lymphoma who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing SHR2554 Tablets for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing SHR2554 combined with Liposomal Mitoxantrone for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing the combination of SHR-0302 (JAK inhibitor) and SHR-2554 (EZH2 inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing genotype-guided targeted agents added to CHOP chemotherapy (different agents matched to genetic subtypes) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing reduced-intensity radiotherapy for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Azacytidine plus CAOLD regimen for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Go-CHOP (Golidocitinib plus Cyclophosphamide for patients with enteropathy-associated T-cell lymphoma who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Alectinib for patients with anaplastic large cell lymphoma (ALCL) at various stages of their disease. This is a Phase 2/3 trial that tests how well the treatment works and may compare it to standard care. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CD5-directed CAR-T cell therapy for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing Selinexor for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing zeprumetostat (EZH2 inhibitor) in combination therapy for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing CD7-directed CAR-T cell therapy for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing VG712 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.